This article has been published jointly by invitation and consent in both the Journal of Clinical Oncology and the Annals of Oncology. Copyright © 2004 American Society of Clinical Oncology and European Society of Medical Oncology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the American Society of Clinical Oncology or the European Society of Medical Oncology
Recommendations for a Global Core Curriculum in Medical Oncology
ESMO/ASCO Task Force on Global Curriculum in Medical Oncology
1 Copenhagen University Hospital, Copenhagen, Denmark; 2 Memorial Sloan-Kettering Cancer Center, New York, NY; 3 University of Vermont, Burlington, VT, USA; 4 Stradins University Hospital, Riga, Latvia; 5 AZ Middelheim, Brussels, Belgium; 6 Universitätisspital, Labor für Onkologie, Zurich, Switzerland
* Correspondence to: Dr H. H. Hansen, University Hospital of Copenhagen, The Finsen Centre, 5072, Blegdamsvej 9, 2100 Copenhagen, Denmark. Email: hansenhh@rh.dk
| The first 150 words of the full text of this article appear below. |
- 1. Introduction
- 2. Standard requirements
- 3. Special requirements
- 3.1 Program leader
- 3.2. Faculty
- 3.2.1 Faculty members
- 3.2.2 Faculty standards
- 3.3 Educational program
- 3.3.1 Educational environment
- 3.3.2 Professionalism—Ethics
- 3.3.3 Responsibility
- 3.3.4 Institutional requirements
- 3.3.4.1 Clinical setting
- 3.3.4.2 Hospital facilities
- 3.3.5 Update of skills and knowledge
- 3.3.6 Perception of other specialities
- 3.3.7 Facilities
- 4. Competency comprising curriculum
- 4.1 Basic scientific principles
- 4.1.1 Cancer biology
- 4.1.2 Tumor immunology
- 4.1.3 Etiology, epidemiology, screening, and prevention
- 4.1.4 Clinical research including statistics
- 4.2 Basic principles in the management and treatment of malignant diseases
- 4.2.1 Pathology/laboratory/medicine/molecular biology medicine
- 4.2.2 Staging procedures
- 4.2.3 Therapy
- 4.2.3.1 Surgery
- 4.2.3.2 Radiation oncology
- 4.2.3.3 Anticancer agents
- 4.2.3.4 Biologic therapy
- 4.2.3.5 Supportive and palliative measurements
- 4.2.3.5.1 Supportive measures
- Nausea and vomiting
- Infections and neutropenia
- Anemia
- Thrombocytopenia
- Marrow and peripheral-blood progenitor cells
- Organ protection
- Mucositis
- Malignant effusions
- Extravasation
- Oncologic emergencies
- Paraneoplastic syndromes
- Nutritional support
- 4.2.3.5.2 Palliative care and end-of-life care
- Pain
- Other symptoms
- Communication
. . . [Full Text of this Article] - 2. Standard requirements
2. Standard requirements for training in medical oncology
3. Special requirements
3.1 Program leader
3.2 Faculty
3.2.1 Faculty members
3.2.2 Faculty standards
3.3 Educational program
3.3.1 Educational environment
3.3.2 Professionalism—ethics
3.3.3 Responsibility
3.3.4 Institutional requirements
3.3.4.1 Clinical setting
3.3.4.2 Hospital facilities
3.3.5 Update of skills and knowledge
3.3.6 Perception of other specialities
3.3.7 Facilities
4. Competency comprising curriculum
4.1 Basic scientific principles
4.1.1 Cancer biology
4.1.2 Tumor immunology
4.1.3 Etiology, epidemiology, screening, and prevention
4.1.4 Clinical research including statistics
4.2 Basic principles in the management and treatment of malignant diseases
4.2.1 Pathology/laboratory medicine/molecular biology
4.2.2 Staging procedures
4.2.3 Therapy
4.2.3.1 Surgery
4.2.3.2 Radiation oncology
4.2.3.3 Anticancer agents
4.2.3.4 Biologic therapy
4.2.3.5 Supportive and palliative measurements
4.2.3.6 Rehabilitation
4.3 Management and treatment of individual cancers
4.3.1 Head and neck cancers
4.3.2 Lung cancer and mesothelioma
4.3.2.1 Small-cell lung cancer
4.3.2.2 Non-small-cell lung cancer
4.3.2.3 Mesothelioma
4.3.3 Gastrointestinal cancers
4.3.3.1 Esophageal cancer
4.3.3.2 Gastric cancer
4.3.3.3 Colon cancer
4.3.3.4 Anal cancer
4.3.3.5 Hepatobiliary cancers
4.3.3.6 Pancreatic cancer
4.3.4 Genitourinary cancers
4.3.4.1 Renal cell cancer
4.3.4.2 Urothelial cancers
4.3.4.3 Penile cancer
4.3.4.4 Prostate cancer
4.3.4.5 Germ cell tumors
4.3.5 Gynecologic malignancies
4.3.5.1 Ovarian cancer
4.3.5.2 Uterine cancer
4.3.5.3 Cervical cancer
4.3.5.4 Vulvar and vaginal cancers
4.3.6 Breast cancer
4.3.7 Sarcomas
4.3.7.1 Bone sarcomas
4.3.7.2 Soft tissue sarcomas
4.3.8 Skin cancers
4.3.8.1 Melanoma
4.3.8.2 Basal cell and squamous cell cancers
4.3.9 Endocrine cancers
4.3.10 Central nervous system malignancies
4.3.11 Carcinoma of unknown primary site
4.3.12 Hematologic malignancies
4.3.12.1 Leukemia
4.3.12.2 Lymphomas
4.3.12.3 Plasma cell dyscrasias
4.3.13 AIDS-associated malignancies
5. Psychosocial aspects of cancer
6. Patient education
6.1 Genetic counselling
6.2 Health maintenance
6.3 Long-term complications
6.3.1 Risk of treatment-induced cancers. Acute myeloid leukemia after chemotherapy, and radiation induced sarcomas
6.3.2 Endocrine dysfunctions Hypothyroidism after neck radiation, sterility with chemotherapy
6.4 Chemoprevention measures/clinical trials
6.5 Testing and intervals for follow-up
7. Bioethics, legal, and economic issues
7.1 Informed consent
7.2 Ethics
7.3 Legal issues
7.4 Cost efficiency
7.5 Conflict of interest
7.6 Professional attitude
8. Skills
8.1 Anticancer agent administration
8.2 Bone marrow aspiration, biopsy, and interpretation
8.3 Ommaya reservoir and lumbar puncture
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E Bajetta, A Gevorgyan, and H Mellstedt National integration of European standards Ann. Onc., June 1, 2007; 18(6): 969 - 970. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kerr Concordia res parvae crescent Ann. Onc., January 1, 2006; 17(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kosmidis, H. Ludwig, and H. Mellstedt ESMO at 30: Mission ongoing Ann. Onc., September 1, 2005; 16(9): 1411 - 1412. [Full Text] [PDF]
|
|
|
|
|
|
H. Ludwig A Foundation for the future Ann. Onc., January 1, 2005; 16(1): 3 - 3. [Full Text] [PDF]
|
|